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SUMMARY - Thrombolysis with intravenous recombinant tissue plasminogen activator (rt-
PA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cere-
brovascularlesion. At University Department ofNeurology, Sestre milosrdnice University Hospital,
Zagreb, thrombolytic therapy with intravenous rtPA (alteplase) (Actrlyse") for acute ischemic stroke
was introduced in 2004. We present our results referring to demographic, time logistics and clinical
outcome data as part of SITS-MOST (Safe Implementation ofThrombolysis in Stroke - MOnito-
ring STudy) and compare them with the results from other centers in Croatia and all other participa-
ting centers. Up to now, 56 patients (61% ofmale and 39% offemale, average age 67 years) have been
treated at our department with intravenous rt-PA (0.9 mg/kg body weight, maximum 90 mg). with
10% ofthe dose given as a bolus followed by 60-minute infusion. Our experiences with thrombolytic
therapy with intravenous rt-PA (alteplase) (Aculyse") for acute ischemic stroke confirm the safety
and the efficacy of this therapy.
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Thromboembolic occlusion of an artery leading to
the brain or in the brain is a major cause of ischemic
stroke. The size and site of the occlusion and the effi-
ciency of compensatory flow through collateral arter-
ies determine the amplitude and extension of the drop
in the blood flow. Reperfusion should be done as early
as possible to avoid cerebral lesion and complications
caused by ischemic injury to the blood vessel walls and
blood-brain barrier'. Thrombolysis with intravenous
recombinant tissue plasminogen activator (rt-PA) is
the first evidence based treatment for acute stroke,
which aims to reduce the cerebrovascular lesion".
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Thrombolytic therapy for stroke was first reported
in 19583 , and a subsequent small trial was reported
in 1963 in the absence of brain parenchymal imag-
ing but guided by angiography". The later arrival of
CT scanning was an enabling technological event and
early dose-finding trials were begun in the 1980s5 ,
with large randomized trials conducted a decade later.
Results of randomized trials of streptokinase therapy
for ischemic stroke were uniformly negative 6-s. Re-
sults of trials of tissue plasminogen activator (tPA)
were mixed in their respective primary analysis9-13 ,
but generally showed a benefit that wanes as the time
from symptom onset to treatment e1apses14,15 . A meta-
analysis of randomized controlled trials showed that
55 fewer patients per 1000 treated with tPA within
6 hours after stroke would be dead or dependent at
the end of follow up compared with patients admin-
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Table 1. Demographic and baseline data
Thrombolysis for acute ischemic stroke - our experiences as part of SITS-MOST
Demographic and baseline data Sestre milosrdnice University Hospital Croatia All centers
Total number of patients treated 56 85 29616
Dose given per patient (mg) (median) 75.0 76.5 68.0
Dose given per kg (mg/kg) 0.9 0.9 0.9
Table 2. Rankin before stroke onset
Rankin before stroke onset




Moderate to severe disabilities
Severe disabilities







Previous din. dg. ischemic stroke
Atrial fibrillation
Congestive heart failure
Table 4. Baseline NIHSS





















































Table 5. Blood pressure at baseline















Blood pressure at baseline (mean, mm Hg)
Systolic
Diastolic
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Table 6. Stroke subgroups
Subgroup
Large vessel disease with significant carotid
stenosis
Large vessel disease, other
Cardiac source of emboli
Small vessel disease (lacunar)
Other/unusual cause
None of the above (can be multiple causes)
Table 7. Time delay
Thrombolysis for acute ischemic stroke - our experiences as part of SITS-MOST







Time delay (minutes) (median)
Stroke onset - arrival to hospital (door time)
Door to imaging study time
Imaging study to report time
Door to treatment/needle time
Stroke onset to treatment - needle time
Table 8. NIHSS changeswithin 24 h












NIHSS changes within 24 h
Change in NIHSS 0-2 h (median)
Change in NIHSS 0-24 h (median)
Significant early improvements (%)*
Significant deterioration (%)*















"Significant early improvement - significant improvement based on NIHSS,i.e. change <= 4 between 0 and 2 hours, 0 and 24 hours, and 2 and 24
hours, or full recovery (end state NIHSS=O).
"Significant deterioration - significant deterioration based on NIHSS, i.e. NIHSS change >=4 between 0 and 2 hours, 0 and 24 hours, 2 and 24
hours or death <=24 h.
Table 9. Global outcome (24 h)
Global outcome (24 h)
Improvement -NIHSS score changed <4
Improvement - NIHSS score changed <2
Unchanged NIHSS score
Deterioration - NIHSS score changed >2
Much worse
Dead
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Table 10. Global outcome (7 days)
Thrombolysis for acute ischemic stroke - our experiences as part of SITS-MOST
Global outcome (7 days)
Improvement -NIHSS score changed <4
Improvement - NIHSS score changed <2
Unchanged NIHSS score
Deterioration - NIHSS score changed>2
Deterioration - NIHSS score changed >4
Dead
Table 11. Rankin 3 months
Rankin 3 months
No symptoms at all



















































istered placebo16,17. Systematic reviews of randomized
controlled trials indicate that treatment with throm-
bolytics is highly beneficial when administered within
3 hours from the onset of stroke symptoms".
Current guidelines for the management of patients
with acute ischemic stroke published by the American
Heart Association Stroke Council include specific
recommendations for the administration of recombi-
nant tissue plasminogen activator (rtPA), on behalf of
Science Advisory from the American Heart Associa-
tion and American Stroke Association.
Despite its effectiveness in improving neurologic
outcomes, the majority of patients with ischemic
stroke are not treated with rtPA, largely because they
arrive after the currently approved 3-hour time limit
for administration of the medication. One of the po-
tential approaches to increase treatment opportunities
has been the designation of a longer time window for
treatment.
A recent prospective study, the European Coop-
erative Acute Stroke Study (ECASS)-3, has provided
new data on rtPA (alteplase) (Actilyse'") treatment
within the 3-to-4.5-hour window. Patients that are
eligible for treatment with rtPA within 3 hours of the
onset of stroke should be treated as recommended in
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the 2007 guidelines!9 Although a longer time win-
dow for treatment with rtPA has been tested formal-
ly, delays in the evaluation and initiation of therapy
should be avoided, because the opportunity for im-
provement is greater with earlier treatment. rtPA
should be administered to eligible patients that can
be treated within the time period of 3 to 4.5 hours af-
ter stroke. The eligibility criteria for treatment in this
time period are similar to those for persons treated at
earlier time periods, with any of the following addi-
tional exclusion criteria: patients older than 80 years,
those taking oral anticoagulants with an international
normalized ratio ?1.7, those with a baseline National
Institutes of Health Stroke Scale (NIHSS) score >25,
or those with a history of both stroke and diabetes.
The relative utility of rtPA in this time window com-
pared with other methods of thrombus dissolution or
removal has not been established. The efficacy of in-
travenous treatment with rtPA within 3 to 4.5 hours
after stroke in patients with these exclusion criteria is
not well established-v".
SITS (Safe Implementation of Thrombolysis in
Stroke) is an academic-driven, non-profit, international
collaboration. It is an initiative by the medical profes-
sion to certify excellence in acute stroke treatment. It
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started as an initiative by part icipants in the Europe-
an-Austra lian randomized stroke th rombolysis stud ies
(ECASS) and then spread to many centers in several
count ries. SITS init iated an internet-based interac-
tive thrombolysis reg ister, to serve as an instrument for
clinical centers to follow their own treatment results
and compare with other centers in their countries and
in the collaborat ing countries. The SITS register is now
the techn ical basis for the International Stroke Throm-
bolysis Register (SITS-IST R) and SITS Monitoring
Study (SITS-M O ST). SITS-M O ST has strict entry
criteria, with a limit of maxima lly three hours from the
onset of symptoms to treatment. The aims of SITS-
MOST are to evaluate the safety and efficacy of routine
use of rt-PA for this well defined population, to evalu-
ate the effect of rt-PA with in defined subgroups of this
popu lat ion , at experienced clinical centers and centers
with less experience but high-qu ality general stroke
care, and to compare these results with those from ran-
domized controlled trials. SITS-MOST also aims to
prove that rtPA is as safe and as beneficial in routine
clinical practice in a large number of European clini-
cal centers as it has been shown to be in randomized
clinical trials such as the National Institute of Neuro-
log ical Disorders Stroke (NIN DS) trial. Part icipation
in SITS -M OST requires agreement of the Nat ional
Coordinator. The International C oord inating center is
at the Karolinska Hospital24,2S.
At University Department of Neurology, Sestre
milosrdnice University H ospital, Zagreb, thro mbolytic
therapy wit h intravenous rtPA (alteplase) (Acti lyse'P)
for acute ischemic stroke was intro duced in 200 4.
According to recommendations for stroke manage-
ment endorse d by C roatian Society for Neurovascu lar
Disorders of Croatian M edical Association, Croatian
Stroke Society and University Depart ment of Neurol-
ogy, Sestre milosrdnice University H ospital as Refer-
ence Center for Neurovascular Disorders of C roatian
Ministry of H ealth, published in 2001, thrombolyt ic
treatment for acute ischem ic stro ke with in 3 hours of
onset was indicated as therapy of choice for all pa-
tients that are eligible for treatment-s.
\Ve present our results as part of the SITS-MOST
study in order to compare them wit h the results from
other centers in Croatia and all other participating
centers. Up to now, 56 pat ients (61% of male and 39%
of female, average-age 67 years) have been treated at
our department with intravenous rt-PA (0.9 mg/kg
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body weight, maximu m 90 mg), with 10% of the dose
given as a bolus followed by 60-minute infusion. The
average dose given per pat ient at our department was
75 mg (Tab le 1).
D emographi c and Baseline Details
\ Ve present demographic and basel ine details from
our center as compared to other centers in Croatia and
all centers, according to Rankin before stroke onset,
stroke risk factors, baseline NI HSS, blood pressure at
baseline and stroke subgroups (Tables 2- 6):
Time Logistics/Time Delay
A s far as the average tim e from the onset of stroke
symptoms to rtPA treatment is concerned, we share
the same results as ot her centers in C roatia, whereas
in all ot her par ticipating centers this time was shor ter.
Time logistics is present as shown in Table 7.
Results - Clinical Outcom e
There were no differences in the early improve-
ment as expressed by improvement of NI HSS score
status betwe en our patients and patients from other
centers in Cro atia and all centers. We report a lower
percentage of early deterioration. The results related to
clin ical outcome considering N IHSS changes within
24 hours, globa l outcome with in the first 24 hours
and 7 days, and Rankin after 3 mont hs are presented
in Tables 8-11.
At our department, asymptomatic intracranial
hemorrhage occurre d in only 4 patients. Using pat ient
selection accord ing to the standard protocol, we re-
corded no death wit hin 7 days of rt-PA treatment.
Our experiences with thrombolytic therapy with
intravenous recombinant tissue-type plasminogen ac-
tivator (alreplase) (Actilyses') in acute ischemic stroke
confirm the safety and efficacy of this therapy, showing
that complications are mi nimal if the Croatian Society
for Stroke Prevent ion (CSSP), European Stroke Orga-
nization (ESO) and AHAIASA gu idelines are strictly
followed. Being a part of the SITS-MOST trial serves
as an instrument to follow our own treatment results
and compare them with other centers in our country
and in the collaborating countries, all with the same
goal to argue for more widespread development and
tra ining of stroke physicians to deliver thrombolytic
therapy to people experiencing acute ischemic stroke.
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In conclusion, we are very happy to take active part
in the exciting time in neurology, stroke in particular,
and to be able to convey our enthusiasm for our re-
search and the results obtained so far.
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Sazetak
TROMBOLIZA KOD AKUTNOG ISHEMIJSKOG MOZDANOG UDARA - NASA ISKUSTVA KAO DIO
PRISTUPA SITS-MOST
M. Roje-Bedekovrc, V. Vargek-Solter, L. Cone, K. Sabolek, T. Breitenfeld, V. Supanc i V. Demarin
Tromboliza intravenskim rekombiniranim aktivatorom tkivnog plazminogena (rt-PA) je prvi dokazani ucinkoviti na-
em lqecenja akutnog ishemijskog mozdanog udara u svrhu smanjenja cerebrovaskularnog ostecenja. U Klinici za neurolo-
giju Klinicke bolnice "Sestre milosrdnice", Zagreb, tromboliticka terapija intravenskim rt-PA-om (alteplase) (Actrlysev) u
bolesnika s akutnim ishemijskim moidanim udarom zapocela je 2004. godine. Predstavljamo nase dosadasnje rezultate,
koji se odnose na demografske, vremenske i podatke 0 kl inickom ishodu bolesnika, prikupljene u sklopu SITS-MOST
(Safe Implementation ofThrombolysis in Stroke - Monitoring STudy) istrazrvanja. u svrhu usporedbe rezultata dobivenih
u nasem centru s rezultatima iz drugih centara Hrvatske i svijeta. Do sada [e u nasem centru trombolizom intravenskim
rt-PA-om (0,9 mg/kg tjelesne tezme, do maksimalno 90 mg). 10% doze primijenjene u bolusu, 90% doze u infuziju u
trajanju od 60 minuta, lqeceno 56 bolesnika (61% muskarci, 39% zene, prosjecne zrvotne dobi 67 godina). Nasa iskustva u
trombolrticko] terapiji (alteplase) (Acrdyse") u bolesnika sa akutnim ishemijskim mozdanim udarom potvrduju ucinkovi-
tost i sugurnost takvog nacina hjecenja.
Kljucne rijeci: Moidana ishemiJa - terapiJa liJekovima; Moidani udar - terapiJa liJekovima; Tiomboliticna terapiJa; Fibri-
nolitici - terapiJskaprimjena
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